Comprehensive Guidelines for the Development of Drugs and Biological Products to Combat COVID-19: Industry Insights The FDA’s recommendations concentrate on phases 2 and 3 trials, encompassing critical elements such as trial population, design, efficacy endpoints, safety considerations, and statistical aspects. In the case of biological products, including cellular and gene therapies and blood products, sponsors […]

2023: A Year of Regulatory Revolution in Life Sciences 2023 was a whirlwind year for the life sciences industry, with regulatory changes and advancements coming at a breakneck pace. Here’s a quick throwback on some of the key highlights: Regulatory Landscape: EU MDR/IVDR Implementation: The long-awaited implementation of the Medical Device Regulation (MDR) and In

In the ever-evolving landscape of global healthcare, a promising update has emerged, marking a significant step forward in the journey toward faster access to life-saving medications. The Therapeutic Goods Administration (TGA) in Australia has recently shared exciting news about the progress of the Promise Pilot Pathway. This update not only highlights the pathway’s continued development

In the realm of life sciences, artificial intelligence (AI) has long been a cornerstone, driving advancements in drug discovery, clinical trial optimization, and personalized patient care. However, a new player has entered the scene, ushering in a wave of innovation that is reshaping the regulatory landscape: Generative AI. While this technology holds the promise of